Skip to content

Chinese PD-LRRK2 Registry

The Chinese Parkinson's Disease With LRRK2 Variants Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03523104
Enrollment
1000
Registered
2018-05-14
Start date
2017-02-01
Completion date
2027-02-01
Last updated
2018-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

The purpose of the Chinese PD-LRRK2 Registry(CPD-LRRK2R) is to develop a database of patients of Parkinson's disease with leucine-rich repeat kinase 2 (LRRK2) gene variants in mainland China.

Detailed description

Parkinson's disease (PD) is the second most common disorder among neurodegenerative diseases. LRRK2 missense mutations are the most common known genetic cause of PD. However, some polymorphisms of LRRK2 such as G2385R and R1628P can also affect the risk of developing PD. The investigators aim to establish a database of PD with LRRK2 variants and characterize the clinical manifestation of these patients in mainland China. Method: 1. Peripheral blood from patients has been tested to have LRRK2 gene variants. 2. Clinical manifestation will be measured by scales and neurological tests. Standard scales include: Unified Parkinson's Disease Rating Scale(UPDRS), Hoehn-Yahr stages, Non-Motor Symptoms Scale (NMSS), mini-mental state examination (MMSE), Parkinson disease sleep scales (PDSS), Rapid Eye Movement Sleep Behaviour Disorder Questionnaire(RBDQ-HK), Epworth Sleepiness Scale (ESS), Rome III functional constipation scale, the Scale for Outcomes in PD for Autonomic Symptoms (SCOPA-AUT), Parkinson Fatigue Scale (PFS), Cambridge-Hopkins Restless Legs Syndrome questionnaire (CHRLSq), Hyposmia rating scale(HRS), Hamilton depression scale, the 39-item Parkinson's Disease Questionnaire(PDQ-39), Freezing of gait scale(FOG), dyskinesia related scales, Wearing-off scale(WO). 3. The investigators will also exam the blood biomarkers of PD such as uric acid and peripheral inflammatory markers.

Interventions

None listed

Sponsors

Xiangya Hospital of Central South University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients diagnosed with PD by the United Kingdom Parkinson's Disease Society Brain Bank clinical diagnostic criteria or other standard criteria; PD patients detected with positive LRRK2 variants

Exclusion criteria

\-

Design outcomes

Primary

MeasureTime frameDescription
Database of Parkinson's disease with LRRK2 variants10 yearsEstablish the database of Parkinson's disease with LRRK2 variants in mainland China.
Clinical feature10 yearsCharacterize the clinical feature in patients of Parkinson's disease with LRRK2 variants

Countries

China

Contacts

Primary ContactJifeng Guo, Ph.D.
guojifeng2003@163.com+8613974936815
Backup ContactBeisha Tang, Ph.D.
bstang7398@163.com+8613974856709

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026